The SCF
Apoptosis
/ drug effects
CASP8 and FADD-Like Apoptosis Regulating Protein
/ metabolism
Caspase 8
/ metabolism
Cell Line, Tumor
Cullin Proteins
/ metabolism
Cyclopentanes
/ pharmacology
Death Domain Receptor Signaling Adaptor Proteins
/ metabolism
Humans
Protein Binding
/ drug effects
Protein Interaction Mapping
Proteolysis
/ drug effects
Pyrimidines
/ pharmacology
Receptors, TNF-Related Apoptosis-Inducing Ligand
/ metabolism
S-Phase Kinase-Associated Proteins
/ metabolism
Signal Transduction
/ drug effects
TNF Receptor-Associated Factor 2
/ metabolism
TNF-Related Apoptosis-Inducing Ligand
/ pharmacology
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
04
12
2019
accepted:
31
03
2020
revised:
30
03
2020
pubmed:
22
4
2020
medline:
24
9
2021
entrez:
22
4
2020
Statut:
ppublish
Résumé
TRAIL-R2 (DR5) is a clinically-relevant therapeutic target and a key target for immune effector cells. Herein, we identify a novel interaction between TRAIL-R2 and the Skp1-Cullin-1-F-box (SCF) Cullin-Ring E3 Ubiquitin Ligase complex containing Skp2 (SCF
Identifiants
pubmed: 32313199
doi: 10.1038/s41418-020-0539-7
pii: 10.1038/s41418-020-0539-7
pmc: PMC7429845
doi:
Substances chimiques
CASP8 and FADD-Like Apoptosis Regulating Protein
0
Cullin 1
0
Cullin Proteins
0
Cyclopentanes
0
Death Domain Receptor Signaling Adaptor Proteins
0
Pyrimidines
0
Receptors, TNF-Related Apoptosis-Inducing Ligand
0
S-Phase Kinase-Associated Proteins
0
TNF Receptor-Associated Factor 2
0
TNF-Related Apoptosis-Inducing Ligand
0
TNFRSF10B protein, human
0
Caspase 8
EC 3.4.22.-
pevonedistat
S3AZD8D215
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2726-2741Subventions
Organisme : Cancer Research UK
ID : C11884/A24387
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C212/A13721
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S021205/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 24387
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/T002824/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 110371/Z/15/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400302
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17117
Pays : United Kingdom
Références
Vaux DL, Korsmeyer SJ. Cell death in development. Cell Cell Press. 1999;96:245–54. https://www.sciencedirect.com/science/article/pii/S0092867400805644?via%3Dihub .
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41. http://www.ncbi.nlm.nih.gov/pubmed/18073771 .
doi: 10.1038/nrm2312
Humphreys L, Espona-Fiedler M, Longley DB. FLIP as a therapeutic target in cancer. FEBS J. 2018. http://www.ncbi.nlm.nih.gov/pubmed/29806737 .
Riley JS, Malik A, Holohan C, Longley DB. DED or alive: assembly and regulation of the death effector domain complexes. Cell Death Dis. 2015;6:e1866 http://www.nature.com/doifinder/10.1038/cddis.2015.213 .
doi: 10.1038/cddis.2015.213
Keller N, Mareš J, Zerbe O, Grütter MG. Structural and biochemical studies on procaspase-8: new insights on initiator caspase activation. Structure. 2009;17:438–48. http://www.ncbi.nlm.nih.gov/pubmed/19278658 .
doi: 10.1016/j.str.2008.12.019
McLornan DP, et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res. 2010;16:3442–51. http://www.ncbi.nlm.nih.gov/pubmed/20570920 .
doi: 10.1158/1078-0432.CCR-10-0052
McCarthy MM, et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005;11:5188–94.
doi: 10.1158/1078-0432.CCR-05-0158
Spierings DCJ, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–405.
Leverkus M, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000;60:553–9. http://www.ncbi.nlm.nih.gov/pubmed/10676636 .
pubmed: 10676636
Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–63. http://www.nature.com/articles/nm0299_157 .
doi: 10.1038/5517
Tolcher AW, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007;25:1390–5.
doi: 10.1200/JCO.2006.08.8898
Plummer R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007;13:6187–94.
doi: 10.1158/1078-0432.CCR-07-0950
Kumar S, Yoshida Y, Noda M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem Biophys Res Commun. 1993;195:393–9. http://www.ncbi.nlm.nih.gov/pubmed/8395831 .
doi: 10.1006/bbrc.1993.2056
Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155–61. http://www.ncbi.nlm.nih.gov/pubmed/1378265 .
doi: 10.1016/0006-291X(92)91747-E
Hori T, et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene. 1999;18:6829–34. http://www.ncbi.nlm.nih.gov/pubmed/10597293 .
doi: 10.1038/sj.onc.1203093
Jones et al. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J Proteome Res. 2018;7:1274–87. http://www.ncbi.nlm.nih.gov/pubmed/18247557 .
Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nat. 2009;458:732–73. http://www.nature.com/doifinder/10.1038/nature07884 .
doi: 10.1038/nature07884
Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6:9–20. http://www.ncbi.nlm.nih.gov/pubmed/15688063 .
Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14:233–47. http://www.nature.com/doifinder/10.1038/nrc3700 .
doi: 10.1038/nrc3700
Lafont E, Hartwig T, Walczak H. Paving TRAIL’s path with ubiquitin. Trends Biochem Sci. 2017;43:44–60. Available from https://doi.org/10.1016/j.tibs.2017.11.002 .
doi: 10.1016/j.tibs.2017.11.002
Jin Z, et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 2009;137:721–35.
doi: 10.1016/j.cell.2009.03.015
Brownell JE, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37:102–11.
doi: 10.1016/j.molcel.2009.12.024
Wilson TR, et al. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene. 2009;28:63–72. http://www.nature.com/articles/onc2008366 .
doi: 10.1038/onc.2008.366
Majkut J, et al. Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly. Nat Commun. 2014;5:3350. http://www.nature.com/articles/ncomms4350 .
doi: 10.1038/ncomms4350
Gonzalvez F, et al. TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a Ubiquitin shutoff timer. Mol Cell. 2012;48:888–99.
doi: 10.1016/j.molcel.2012.09.031
Schuler S, et al. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int J Oncol. 2011;38:219–25. http://www.spandidos-publications.com/ijo/38/1/219 .
pubmed: 21109943
Hughes MA, et al. Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell. 2016;61:834–49.
doi: 10.1016/j.molcel.2016.02.023
Henry CM, Martin SJ. Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory “FADDosome” complex upon TRAIL stimulation. Mol Cell. 2017;65:715–29.e5.
doi: 10.1016/j.molcel.2017.01.022
Yu JW, Jeffrey PD, Shi Y. Mechanism of procaspase-8 activation by c-FLIPL. Proc Natl Acad Sci USA. 2009;106:8169–74.
doi: 10.1073/pnas.0812453106
Humphreys LM, et al. A revised model of TRAIL ‐R2 DISC assembly explains how FLIP (L) can inhibit or promote apoptosis. EMBO Rep. 2020;21:e49254. https://doi.org/10.15252/embr.201949254 .
Carson R, et al. HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL. Clin Cancer Res. 2015;21:3230–40. http://www.ncbi.nlm.nih.gov/pubmed/25813020 .
doi: 10.1158/1078-0432.CCR-14-2701
Crawford N, et al. SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma. Cell Death Dis. 2013;4:e733. http://www.nature.com/articles/cddis2013258 .
doi: 10.1038/cddis.2013.258
Paul I, et al. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis. 2012;3:e449. http://www.nature.com/articles/cddis2012186 .
doi: 10.1038/cddis.2012.186
McLaughlin KA, et al. FLIP: a targetable mediator of resistance to radiation in non-small cell lung cancer. Mol Cancer Ther. 2016;15:2432–41. http://www.ncbi.nlm.nih.gov/pubmed/27474150 .
doi: 10.1158/1535-7163.MCT-16-0211
Poukkula M, et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem. 2005;280:27345–55. http://www.ncbi.nlm.nih.gov/pubmed/15886205 .
doi: 10.1074/jbc.M504019200
Mohr A, et al. Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment. Cell Death Differ. 2018;25:340–52.
doi: 10.1038/cdd.2017.164
Chang L, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIPL turnover. Cell. 2006;124:601–13.
doi: 10.1016/j.cell.2006.01.021
Santini S, et al. ATM kinase activity modulates ITCH E3-ubiquitin ligase activity. Oncogene. 2014;33:1113–23.
doi: 10.1038/onc.2013.52
Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2012;2:140–55. http://www.ncbi.nlm.nih.gov/pubmed/22585859 .
doi: 10.1158/2159-8290.CD-11-0172
Xu L, et al. DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. Mol Oncol. 2017;11:1733–51. http://www.ncbi.nlm.nih.gov/pubmed/28972304 .
doi: 10.1002/1878-0261.12140
Tschopp J, Kataoka T. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically Interacts with TRAF2 and induces activation of the NF-kB signaling pathway. Mol Cell Biol. 2004;24:2627–36.
doi: 10.1128/MCB.24.7.2627-2636.2004